Trial · NCT01711879
Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma
NCT01711879, Not applicable, Completed, University of Colorado, Denver; results first posted 2021-01-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma. Trials, record NCT01711879. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01711879
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma
- NCT number
- NCT01711879
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 7 participants, actual
- Lead sponsor
- University of Colorado, Denver
- Conditions
- Neovascular Glaucoma
- Interventions
- Aflibercept
- First posted
- 2012-10-22
- Last updated
- 2022-03-18
- Results first posted
- 2021-01-05
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Adverse Events | 2 year | Assess the safety profile of repeated intravitreal aflibercept injections in patients with NVG by evaluating the incidence of adverse events |
| Primary | Severity of Adverse Events | 2 year | Assess the safety profile of repeated intravitreal aflibercept injections in patients with NVG by evaluating the severity of adverse events |
| Secondary | Rate and Extent of Resolution of Neovascularization | 1 year | Compare between Groups A and B the Rate and extent of resolution of neovascularization in patients with NVG Stages 1 \& 2. |
| Secondary | Intraocular Pressure (mmHg) at Baseline | Baseline | Intraocular pressure(mmHg) as measured by Goldmann applanation tonometry between groups A and B |
| Secondary | Intraocular Pressure (mmHg) at Week 52 | Week 52 | Mean intraocular pressure(mmHg) as measured by Goldmann applanation tonometry between groups A and B |
| Secondary | Number of Patients Losing > 5 Letters on Visual Acuity in Each Group A and Group B | Baseline to Week 52 | Comparison between patients, groups A and B, that lost \> 5 letters on visual acuity |
| Secondary | Number of Patients in Each, Group A and Group B, Gaining > 5 Letters on Visual Acuity | Baseline to Week 52 | Comparison of patients in each, group A and group B, that gained \> 5 letters on visual acuity |
| Secondary | Visual Acuity at Baseline | Baseline | Comparison of visual acuity between groups A and B |
| Secondary | Visual Acuity at Week 52 | Week 52 | Comparison of visual acuity at Week 52 between groups A and B |
| Secondary | Comparison of the Visual Field Between Groups | 1 year | Comparison of the Visual field s measured by HVF 24-2 SITA Standards between groups A and B |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes15
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Incidence of Adverse Events | 2 year | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Severity of Adverse Events | 2 year | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Rate and Extent of Resolution of Neovascularization | 1 year | No data was collected or analyzed for this Outcome Measure | ||
| SECONDARY | Intraocular Pressure (mmHg) at Baseline | Baseline | One participant from group Aflibercept with Laser did not complete analysis due to death. Analysis is limited due to small sample size. | mmHg | MEAN |
| SECONDARY | Intraocular Pressure (mmHg) at Week 52 | Week 52 | One participant from group Aflibercept with Laser did not complete analysis due to death. Analysis is limited due to small sample size. | mmHg | MEAN |
| SECONDARY | Number of Patients Losing > 5 Letters on Visual Acuity in Each Group A and Group B | Baseline to Week 52 | One participant from group Aflibercept with Laser did not complete analysis due to death. Analysis is limited due to small sample size. | participants | NUMBER |
| SECONDARY | Number of Patients in Each, Group A and Group B, Gaining > 5 Letters on Visual Acuity | Baseline to Week 52 | One participant from group Aflibercept with Laser did not complete analysis due to death. Analysis is limited due to small sample size. | participants | NUMBER |
| SECONDARY | Visual Acuity at Baseline | Baseline | One participant from group Aflibercept with Laser did not complete analysis due to death. Analysis is limited due to small sample size. | Letters | MEAN |
| SECONDARY | Visual Acuity at Week 52 | Week 52 | One participant from group Aflibercept with Laser did not complete analysis due to death. Analysis is limited due to small sample size. | Letters | MEAN |
| SECONDARY | Comparison of the Visual Field Between Groups | 1 year | No data was collected or analyzed for this Outcome Measure during the clinical trial. |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 outcomesResults by group128
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence of Adverse Events | Aflibercept With Laser | 3 | Participants | ||
| Incidence of Adverse Events | Aflibercept | 4 | Participants | ||
| Severity of Adverse Events | Aflibercept With Laser | Abcess left thigh / Mild | 0 | Participants | |
| Severity of Adverse Events | Aflibercept | Abcess left thigh / Mild | 1 | Participants | |
| Severity of Adverse Events | Aflibercept With Laser | Abcess left thigh / Moderate | 0 | Participants | |
| Severity of Adverse Events | Aflibercept | Abcess left thigh / Moderate | 0 | Participants | |
| Severity of Adverse Events | Aflibercept With Laser | Abcess left thigh / Severe | 0 | Participants | |
| Severity of Adverse Events | Aflibercept | Abcess left thigh / Severe | 0 | Participants | |
| Severity of Adverse Events | Aflibercept With Laser | Abcess left thigh / None | 3 | Participants | |
| Severity of Adverse Events | Aflibercept | Abcess left thigh / None | 3 | Participants |
1 to 10 of 128Source ClinicalTrials.gov
See all 128 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Aflibercept With Laser | 3 | |
| Overall Study | STARTED | Aflibercept | 4 | |
| Overall Study | COMPLETED | Aflibercept With Laser | 2 | |
| Overall Study | COMPLETED | Aflibercept | 4 | |
| Overall Study | NOT COMPLETED | Aflibercept With Laser | 1 | |
| Overall Study | NOT COMPLETED | Aflibercept | 0 |
Source ClinicalTrials.gov
Adverse events28
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Recurrent BCC | Skin and subcutaneous tissue disorders | Aflibercept With Laser | 0 | 3 | 0 |
| other | Recurrent BCC | Skin and subcutaneous tissue disorders | Aflibercept | 1 | 4 | 1 |
| other | Abcess left thigh | Skin and subcutaneous tissue disorders | Aflibercept With Laser | 0 | 3 | 0 |
| other | Abcess left thigh | Skin and subcutaneous tissue disorders | Aflibercept | 1 | 4 | 1 |
| other | Asthma | Respiratory, thoracic and mediastinal disorders | Aflibercept With Laser | 0 | 3 | 0 |
| other | Asthma | Respiratory, thoracic and mediastinal disorders | Aflibercept | 1 | 4 | 1 |
| other | Pneumonia | Respiratory, thoracic and mediastinal disorders | Aflibercept With Laser | 0 | 3 | 0 |
| other | Pneumonia | Respiratory, thoracic and mediastinal disorders | Aflibercept | 1 | 4 | 1 |
| other | Vitreous hemmorrhage | Eye disorders | Aflibercept With Laser | 2 | 3 | 2 |
| other | Vitreous hemmorrhage | Eye disorders | Aflibercept | 0 | 4 | 0 |
1 to 10 of 28Source ClinicalTrials.gov
See all 28 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Aflibercept With Laser | 1 | 3 |
| Total, all-cause mortality | Aflibercept | 0 | 4 |
| Total, other adverse events | Aflibercept With Laser | 3 | 3 |
| Total, other adverse events | Aflibercept | 4 | 4 |
| Total, serious adverse events | Aflibercept With Laser | 1 | 3 |
| Total, serious adverse events | Aflibercept | 0 | 4 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons7
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Aflibercept With Laser vs Aflibercept: Number of Patients in Each, Group A and Group B, Gaining > 5 Letters on Visual Acuity | Trial comparisons |
| Aflibercept With Laser vs Aflibercept: Number of Patients Losing > 5 Letters on Visual Acuity in Each Group A and Group B | Trial comparisons |
| Aflibercept With Laser vs Aflibercept: Number of Patients With Need for Surgical Intervention | Trial comparisons |
| Aflibercept With Laser vs Aflibercept: Incidence of Adverse Events | Trial comparisons |
| Aflibercept With Laser vs Aflibercept: Number of Participants With Need for Additional IOP Lowering Medications | Trial comparisons |
| Aflibercept With Laser vs Aflibercept: deaths from any cause | Trial comparisons |
| Aflibercept With Laser vs Aflibercept: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01711879
GET https://conductscience.org/api/trials/v1/NCT01711879/results?page=2